Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study (2023)
- Authors:
- Autor USP: PEREIRA, JULIANA - FM
- Unidade: FM
- DOI: 10.1182/bloodadvances.2023010330
- Subjects: LINFOMA; INFECÇÕES POR VÍRUS DE DNA; INIBIDORES DE ENZIMAS; APOPTOSE
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Blood advances
- ISSN: 2473-9529
- Volume/Número/Paginação/Ano: v. 7, n. 20, p. 6339-6350, 2023
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
HAVERKOS, Bradley et al. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood advances, v. 7, n. 20, p. 6339-6350, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/57344. Acesso em: 11 fev. 2026. -
APA
Haverkos, B., Alpdogan, O., Baiocchi, R., Brammer, J. E., Feldman, T. A., Capra, M., et al. (2023). Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood advances, 7( 20), 6339-6350. doi:10.1182/bloodadvances.2023010330 -
NLM
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study [Internet]. Blood advances. 2023 ; 7( 20): 6339-6350.[citado 2026 fev. 11 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57344 -
Vancouver
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study [Internet]. Blood advances. 2023 ; 7( 20): 6339-6350.[citado 2026 fev. 11 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57344 - Adult T-Cell Leukemia/Lymphoma: A Clinical and Epidemiological Analysis at the Medicine School of Sao Paulo University
- How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation
- Radiographic patterns of multiple myeloma in the jawbones of patients treated with intravenous bisphosphonates
- GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms
- Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study
- Panoramic and skull imaging may aid in the identification of multiple myeloma lesions
- Estudo de células precuroras em leucemias agudas: identificação e fator de prognóstico das proteínas Bcl-2, Bax e CD95/Fas/APO-1
- 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era
- Immune reconstitution inflammatory syndrome-associated lymphoma: a retrospective Brazilian cohort
- Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
Informações sobre o DOI: 10.1182/bloodadvances.2023010330 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
